相似文献
1
[Interpretiation of guidelines for the diagnosis and management of aplastic anemia in China (2022)].
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):188-192. doi: 10.3760/cma.j.issn.0253-2727.2023.03.003.
2
[Guidelines for the diagnosis and management of aplastic anemia in China (2022)].
Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):881-888. doi: 10.3760/cma.j.issn.0253-2727.2022.11.001.
3
[Treatment of aplastic anemia in children].
Rinsho Ketsueki. 2014 Oct;55(10):1769-76.
4
Diagnosis and treatment of acquired aplastic anemia.
Hematol Oncol Clin North Am. 2009 Apr;23(2):159-70. doi: 10.1016/j.hoc.2009.01.005.
5
Acquired aplastic anemia in children.
Pediatr Clin North Am. 2013 Dec;60(6):1311-36. doi: 10.1016/j.pcl.2013.08.011. Epub 2013 Oct 16.
6
Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP).
Blood Cells Mol Dis. 2015 Jun;55(1):40-7. doi: 10.1016/j.bcmd.2015.03.007. Epub 2015 Mar 31.
7
[Treatment of adult patients with aplastic anemia in Japan].
Rinsho Ketsueki. 2005 Jun;46(6):389-93.
8
Severe fatigue: could it be aplastic anemia?
Clin J Oncol Nurs. 2008 Aug;12(4):569-73. doi: 10.1188/08.CJON.569-573.
9
Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group.
Haematologica. 2011 Jun;96(6):814-9. doi: 10.3324/haematol.2010.035600. Epub 2011 Mar 21.
10
Immunosuppressive therapy for transplant-ineligible aplastic anemia patients.
Expert Rev Hematol. 2015 Feb;8(1):89-99. doi: 10.1586/17474086.2015.978759.
引用本文的文献
1
A real-world pharmacovigilance analysis of hepatitis B vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database.
Sci Rep. 2025 Feb 19;15(1):6022. doi: 10.1038/s41598-025-90135-8.
本文引用的文献
1
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
2
Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.
Front Immunol. 2022 May 26;13:884312. doi: 10.3389/fimmu.2022.884312. eCollection 2022.
3
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
N Engl J Med. 2022 Jan 6;386(1):11-23. doi: 10.1056/NEJMoa2109965.
4
Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Blood. 2022 Jan 6;139(1):34-43. doi: 10.1182/blood.2021012130.
5
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag.
Haematologica. 2022 Jan 1;107(1):126-133. doi: 10.3324/haematol.2021.278413.
6
Young haploidentical donor versus fully matched elderly donor: An observational study on patients aged 50 years or older underwent hematopoietic progenitor cells transplantation.
Transfus Apher Sci. 2021 Apr;60(2):103032. doi: 10.1016/j.transci.2020.103032. Epub 2020 Dec 29.
7
Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China.
Front Pharmacol. 2020 Nov 16;11:582625. doi: 10.3389/fphar.2020.582625. eCollection 2020.
8
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.
Blood Rev. 2021 May;47:100772. doi: 10.1016/j.blre.2020.100772. Epub 2020 Oct 31.
9
Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
Int J Hematol. 2020 Dec;112(6):787-794. doi: 10.1007/s12185-020-02971-1. Epub 2020 Sep 2.
10
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years.
Blood Adv. 2019 Oct 22;3(20):3070-3079. doi: 10.1182/bloodadvances.2019000480.
Zotero 插件